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A B S T R A C T
Rosacea is a chronic inflammatory skin condition that predominantly affects the skin of the face and the
eyes. Several factors are associated with the onset and persistence of the condition, including an altered
immune response in the skin and elevated levels of Demodex mites. Alterations in the immune response
include elevated levels of LL-37 in rosacea skin, increased expression of TLR-2 and increased amounts of
vitamin D3 in epidermal tissue. The combined effect of these changes may make the skin more sensitive
to external and internal stimuli. External stimuli that may trigger or sustain rosacea inflammation
include exposure to ultraviolet light, while internal factors may include the presence of elevated numbers
of Demodex mites. These mites may directly stimulate an immune response or release bacteria within the
pilosebaceous unit that act as a trigger for inflammation. This review will highlight the changes that occur
in the immune response of the skin and describe how Demodex mites and associated bacteria may
activate this response and lead to the characteristics of rosacea.
ã 2015 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights
reserved.
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Rosacea is a chronic cutaneous disorder that primarily affects
the central region of the face and is characterized by chronic
inflammation and fibrosis [1]. The standard classification system
for rosacea describes four distinct clinical subtypes [2].
Erythematotelangiectatic rosacea (ETR) is characterised by flush-
ing and persistent central facial erythema with or without
telangiectasia (Fig. 1). Papulopustular rosacea (PPR) is associatedier Ireland Ltd. All rights reserved.
Fig. 1. Erythemic rosacea showing flushing and redness in the centre of the face.
Fig. 3. Phytamous rosacea with proliferation and inflammation of skin surrounding
nasal passage.
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facial papules or pustules or both (Fig. 2). Phymatous rosacea is
characterized by skin thickening, irregular surface nodularities and
enlargement (Fig. 3). Locations affected include the nose, chin,
forehead, cheeks, and ears. Ocular rosacea, displays symptoms
such as foreign body sensation in the eye, burning or stinging,
dryness, itching, ocular photosensitivity, blurred vision, telangiec-
tasia of the sclera or other parts of the eye, or periorbital oedema
(Fig. 4). While four subtypes of rosacea are recognised patients can
display a number of subtypes simultaneously e.g. ocular rosacea in
erythematotelangiectatic rosacea patients.
The incidence of rosacea in the population may range from less
than 1% to 22%, with a higher prevalence amongst fair-skinned
individuals of northern European or Celtic ancestry [3]. Females
are more likely to suffer the symptoms of rosacea, the onset of
which usually occurs between the ages of 30–50 [4]. Males,
however are at greater risk of developing the phymatous form of
the condition, particularly around the nasal area (rhinophyma)
[3].
Although its aetiology remains unclear, the pathophysiology of
rosacea appears to be dictated by the complex interaction of a
dysfunctional cutaneous-innate immune system and a dysregu-
lated neurovascular system [1,5]. This review will explore some of
the key components that contribute to the development of rosacea
focusing particularly on the role of the cutaneous-innate immune
response, and how certain environmental and microbial stimuli
influence this immune response to produce the phenotypic
characteristics of rosacea.
1.1. The cutaneous immune response
Within the various epidermal layers of the skin multiple cell-
types act synergistically to maintain homeostasis and defend the
host against disease [6]. Epidermal keratinocytes are skin cells thatFig. 2. Papulopustular rosacea showing persistent erythema, teleangiectases,
papules and pustules.primarily dictate the structure of the epidermis but also play a role
as innate immune cells by detecting pathogens and tissue damage.
This process is mediated by pattern recognition receptors (PRRs)
which recognise pathogen-associated molecular patterns (PAMPs)
and danger-associated molecular patterns (DAMPs) respectively
[6]. In normal skin, triggering an innate immune response through
PRRs such as Toll-like receptors (TLRs) normally induces the
carefully controlled expression and release of cytokines, chemo-
kines and antimicrobial peptides (AMPs)—effector molecules that
mediate a proinflammatory response by recruiting and activating
leucocytes [7]. However, individuals with rosacea do not experi-
ence the same tightly regulated inflammatory response. Instead,
the pathophysiology of rosacea appears to be defined by
consistently abnormal innate immune activity which is exempli-
fied by the chronic inflammation associated with the disease [8].
1.2. Cathelicidin/LL37; a major contributor to inflammation in rosacea
Human cathelicidins are multi-functioning proteins that are
stored in the granules of neutrophils and in lamellar bodies of
keratinocytes [9]. The nascent cathelicidin antimicrobial peptide
(CAMP) gene product, hCAP18 is secreted as an inactive pro-
protein, and in normal skin expression is kept low but dramatically
upregulated upon skin-wounding and infection [9]. Enzymatic
processing of hCAP18 generates the biologically active peptide
LL-37, which can be cleaved further, to positively or negatively
modify its antimicrobial activity [10].
LL-37 proteins play a dual role in the innate immune system by
functioning as antimicrobials and as mediators of leucocyte
recruitment [11,12]. Additional roles for LL-37 involve wound-
healing responses including the induction of angiogenesis through
binding formyl peptide receptor-like-1 on endothelial cells and
stimulating the expression of extracellular matrix componentsFig. 4. Ocular rosacea demonstrating eye lid margin inflammation.
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activation of epidermal growth factor receptors leading to vascular
endothelial growth factor synthesis and, in turn, stimulating
vasodilation and angiogenesis [14,15].
Given its influence on proinflammatory- and vaso-activity, LL-
37 activity must be strictly regulated however, cathelicidin
expression levels are significantly higher in the epidermis of
individuals with rosacea than those with normal skin [12]. Thus
these peptides have been implicated as key contributors to
immune dysregulation in the skin of patients with rosacea
[8,12]. Moreover, protein-processing patterns differ and when
compared to normal skin, rosacea skin displays an altered
cathelicidin profile that includes LL-37 and FA-29 [12]. LL-37 is
usually produced in neutrophils activated by injured or infected
skin, however aberrant LL-37 production occurs in cells within the
epidermis of rosacea skin, giving rise to inflammation, erythema
and neovascularization (Fig. 5) [12].
The link between altered LL-37 activity and the inflammation
that is characteristic of rosacea skin was demonstrated by
Yamasaki et al. who injected mice with exogenous LL-37 and
subsequently observed a dose-dependent progression of erythe-
ma, vasodilation and neutrophil infiltration [12]. Furthermore,
mice deficient in the cathelicidin gene CAMP, displayed reduced
inflammation in comparison to wild-type mice when treated with
a chemical irritant. These results suggest a profound role for the
cathelicidin protein, LL-37 in the pathogenesis of rosacea [12].
1.3. Kallikrein-5 (KLK5); the driver of cathelicidin-induced
inflammation
The elevated levels of LL-37 in rosacea skin are attributed to
increased enzymatic activity of the serine protease kallikrein 5
(KLK5), which cleaves the inactive pro-protein hCAP18 to the
biologically active LL-37 peptide [10,12]. Mice deficient in serine
protease inhibitors showed increased KLK5 activity and a
cathelicidin profile similar to that in rosacea, consisting mainly
of GLL-34 (murine LL-37) [12]. In contrast, wild-type mice had no
GLL-34 present in the skin. Moreover, when CAMP/ mice wereFig. 5. Demodex mites and bacteria in the pilosebaceous unit of the facial skin, along
with UV-mediated vitamin D3 production induce TLR2 activation in keratinocytes,
leading the expression of proinflammatory cytokines, chemokines, KLK5 and LL-37.
This results in neutrophil and mast cell chemotaxis, and angiogenesis. Neutrophils
contribute to inflammation by releasing LL-37 and a range of proinflammatory
cytokines as well as MMP3 and MMP9. Mast cells release proinflammatory
cytokines, induce KLK5 production and mediate LL-37 activity. The combined
effects of these events may result in the formation of pustules and localized
inflammation that is characteristic of rosacea.injected with KLK5, the same inflammatory cell infiltrate and
erythema observed in wild-type mice did not occur in the
cathelicidin/ mice [12]. Taken together, these observations
highlight the importance of KLK5 in orchestrating the inflamma-
tion observed in rosacea skin.
1.4. Mast cells facilitate the cycle of inflammation in rosacea
Experimental evidence indicates that LL-37 has a profound
influence on mast cell (MC) activity by inducing MC chemotaxis,
degranulation and proinflammatory cytokine release [16,17]. Muto
et al. demonstrated the relationship between MC and LL-37 by
injecting MC/ mice and wild-type mice with exogenous LL-37
[18]. Unlike the wild-type mouse, no inflammation was observed
in the MC/ animal. However, when MC/ mice were recon-
stituted with MC and subsequently injected with LL-37, inflam-
mation occurred, thus providing strong evidence for the link
between LL-37 and MC activity, and the dependency of each
component on the other to induce inflammation. In vitro experi-
ments demonstrated that MC induce KLK5 production by human
keratinocytes [18]. Furthermore, exposure of MC to LL-37 induced
the release of proinflammatory IL-6 and MMP9 [18] (Fig. 5). Thus
MC appear to feed into a cycle of pro-inflammatory activity driven
largely by LL-37.
Because of their role in instigating and enhancing inflamma-
tion, vasodilation and angiogenesis, the interplay between LL-
37 and MC may have critical implications for the pathogenesis of
rosacea and are potential therapeutic targets [18].
1.5. Overexpression of TLR2 increases the sensitivity of rosacea skin to
external stimuli
Toll-like receptors are key drivers of the innate immune
response and their activation through recognition of PAMPs and
DAMPs trigger signalling cascades, leading to the controlled
release of proinflammatory cytokines, chemokines and AMPs
[7]. Yet despite regular TLR activation by external stimuli such as
the hugely diverse microbial populations that inhabit all skin
types, the chronic inflammation that is typical of rosacea does not
appear on normal skin [8,19].
However, TLR2 expression is far greater on the keratinocytes of
rosacea skin than on normal skin and even on skin with other
inflammatory conditions [19]. TLR2 activation was found to be a
significant regulatory factor of increased KLK5 concentrations and
protease activity. This TLR2-mediated KLK5 activity appears to be
controlled at the post-transcriptional level in a calcium-dependent
manner [19]. Consistent with these observations, TLR2/ mice
showed no increase in KLK5 concentrations upon exposure to
Propionibacterium, the most common microbe on facial skin and an
activator of TLR2 [19]. Moreover, CAMP expression was abrogated
in TLR/ mice, thereby indicating a role for TLR2 in the induction
of cathelicidin genes [19].
1.6. Vitamin D3 stimulates inflammation in rosacea skin
Numerous studies have established a role for 1,25(OH)2 vitamin
D3 in the cutaneous-innate immune-, and wound-healing response
[20,21]. The biologically active form of the vitamin D3 hormone,
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), is produced in the skin
upon exposure to UVB light [22]. Vitamin D receptor elements are
located in the promoter of the CAMP gene and, accordingly 1,25
(OH)2D3 regulates cathelicidin gene expression in keratinocytes
[22,23].
Interestingly, 1,25(OH)2D3 appears to regulate expression of
TLR2 and when human keratinocytes were cultured in the presence
of 1,25(OH)2D3, TLR2 mRNA, but not that of other TLRs, increased
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induces the expression of vitamin D receptors and CYP27B1, the
enzyme required to activate 1,25(OH)2D3 [21]. 1,25(OH)2D3 also
induces KLK5 expression in keratinocytes resulting in increased
LL-37 production [22]. Thus, in addition to directly inducing LL-
37 production,1,25(OH)2D3 also increases expression of TLR2 which,
through mediating KLK5 activity, elevates levels of LL-37 [19,21].
It is well established that UVB radiation is a key exacerbator of
rosacea [8]. This may be explained in part, by increased KLK5 and
LL-37 production induced by 1,25(OH)2D3 upon exposure to
sunlight [21]. Furthermore, increased vitamin D levels have been
identified in the serum of rosacea patients compared to controls,
although larger epidemiological studies to verify the link between
vitamin D serum-concentrations and the pathogenesis of rosacea
were recommended in this study [23].
1.7. Demodex mites in humans
Demodex folliculorum mites live in hair follicles or sebaceous
glands while Demodex brevis mites live individually and are usually
located in the meibomian glands. Demodex mites occur in all
human races, and about 80–90% of the human population is
infected, with colonization reaching 100% in elderly people (36).
The elevated density of Demodex mites in rosacea skin is well
established although the precise impact of the mite on the disorder
remains controversial [24–26]. Abnormal sebum composition may
enable the proliferation of mites in rosacea skin, and lesions may
develop as a result of excessive inflammation triggered by D.
folliculorum in the pilosebaceous unit [26–28].
Several studies have associated increasingly high D. folliculorum
infestation in rosacea skin with a corresponding increase in pro-
inflammatory mediators such as TNF-a, IL-1b, IL-8 and LL-37
[12,26]. Demodex mites may induce an inflammatory response
through the expression of PAMPs displayed on the miteexoskeleton,
or DAMPs caused by epidermal tissue damage when the mites feed
on epithelial cells [29]. Chitin, a polysaccharide contained in the
exoskeleton of insects, is known to activate TLR2 on keratinocytes
[30] and a role for NLRP3 in the pathogenesis of rosaceawas recently
reported byCasas et al. who observedincreasedexpressionof Nalp3,
pro-caspase-1, pro-IL-1b and IL-1b [26]. In this study, individuals
withPPRwerefoundtohavehigherlevelsof IL-8thanthosewithETR
[26]. In addition to inducing angiogenesis, IL-8 promotes neutrophil
chemotaxis and these cells contribute to the development of
inflammatory pustules characteristic of PPR [31].
Due to the fact that rosacea correlates with the increased
abundance of Demodex mites and patients respond well to
antibiotics, it has been speculated that D. folliculorum mites may
be a reservoir of micro-organisms that contribute to the
development of the disease. Demodex mites lack an anus and
the undigested remains are kept inside the mites, thus providing a
micro-environment for a broad range of bacteria in the digestive
system [36]. The internal contents may be released upon death of
the mite. In this way Demodex mites may bring bacteria deep into
the skin where an immune reaction is triggered. This may explain
the host’s inability to effectively eradicate these bacterial
infections since the micro-organisms are constantly passively
transferred by motile Demodex parasites. While the mites
themselves evade the immune system, their presence may result
in a permanent exposure of human immune system to bacterial
antigens, causing a chronic inflammatory condition.
1.8. The potential role of bacteria in rosacea
The effectiveness of antibiotics such as tetracycline as a
treatment for reducing inflammation in rosacea indicates that
inflammatory processes may be driven by bacteria, sincetetracycline does not kill Demodex mites [33]. There are conflicting
opinions about whether the reduction in inflammation is due to
the anti-inflammatory properties or anti-microbial properties of
antibiotics [34,35]. Nevertheless, current data suggests that
bacteria may indeed have a potential role in the pathogenesis of
rosacea [35,36].
Whitfeld et al. reported a role for Staphylococcus epidermidis in
the development of pustules [37]. S. epidermidis strains inhabiting
rosacea skin appear to differ from those in normal skin, and when
grown at 37 C these strains produced an altered protein profile
compared to those grown at 30 C [35]. It was suggested that the
slightly elevated temperature in the facial skin of rosacea patients
may influence the strains of bacteria colonising the skin, hence the
proteins they produce [35].
Demodex mites contain a large and varied population of bacteria
[32] and when the mites die, bacterial antigens may be released
into the pilosebaceous unit, triggering a localised pro-inflamma-
tory response [33]. Since Demodex density is increased in rosacea,
the bacterial load may also be elevated and these high levels of
antigens could aggravate an already aberrant immune response
[33,38]. This may explain why inflammation in cases of papulo-
pustular rosacea is often centred on the pilosebaceous unit where
the Demodex mites are located.
Analysis of the microbiota of Demodex mites obtained from the
skin of individuals with ETR, PPR and normal skin, showed that
microbial diversity differed according to the status of the host’s
skin condition [32]. It has been suggested that Demodex-associated
microbiota may be influenced by the different sebum composition
in rosacea skin [27,32]. Recent research points to a role for the
Demodex-related bacteria Bacillus oleronius, in stimulating proin-
flammatory responses in PPR, ETR and OR [33,38,39]. B. oleronius
was isolated from a D. folliculorum mite extracted from the face of a
patient with papulopustular rosacea [33] and this bacterium was
sensitive to tetracycline, doxycycline and minocycline, commonly
successfully used in the treatment of rosacea. Of specific interest
were B. oleronius-derived 62- and 83 kDa proteins as these seemed
to trigger significant immunoreactivity in the serum of individuals
with rosacea when compared to controls [33,38,39]. Exposure to B.
oleronius proteins induced high rates of neutrophil chemotaxis and
a neutrophil-mediated proinflammatory response involving IL-8,
MMP9, TNF-a and cathelicidins [40].
The potential role of B. oleronius proteins in the development of
corneal ulcers was recently investigated by exposing corneal
epithelial cells (hTCEpi) to Bacillus proteins and this resulted in the
upregulation of several pro-inflammatory cytokines including IL-6,
IL-8, IL-1b and TNF-a [41]. In a separate study using the same cell
line, significant upregulation of MMP3 and MMP9 was observed by
cells exposed to B. oleronius, thus leading to a possible explanation
for the corneal ulcer formation and corneal scarring in individuals
suffering from ocular rosacea [42].
1.9. Therapeutic strategies for rosacea
A number of treatments for rosacea currently exist however
these tend to treat distinct symptoms rather than the underlying
cause(s) [43]. Topical medications such as azelaic acid and
metronidazole have shown effectiveness in the treatment of PPR
by virtue of their anti-inflammatory and antimicrobial properties
[43]. Oral tetracycline antibiotics have shown success in treating
rosacea although it is unclear whether this is because of its
antimicrobial properties, or due to its ability to inhibit protease
(e.g. KLK5) and MMP activity, and thus reduce inflammation
[34,43,44]. Since tetracycline antibiotics are inactive against
Demodex, it is possible that this drug may be acting on a bacterial
element thereby reducing the inflammation in rosacea skin. On the
other hand, oral treatment with a sub-antimicrobial dose of
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release and 10 mg delayed-release beads) has shown to be as
effective as a 100 mg (antimicrobial) dose of doxycycline in
reducing inflammation in individuals with rosacea and this course
of therapy is now approved by the US FDA for the treatment of
rosacea [43,45].
Tea-tree oil (TTO) is a known acaricide and has demonstrated
positive effects in reducing the Demodex infestation and inflam-
mation in patients with blepharitis [46]. Ivermectin is a broad
spectrum antiparasitic drug which also possesses some anti-
inflammatory properties [47]. More recently, the use of topical
ivermectin (1%) was shown to be effective in reducing the
symptoms of PPR [48]. Oral ivermectin has had successful clinical
outcomes in treating Demodex infestations in patients presenting
with blepharitis, resulting in reduced Demodex density and
improved clinical symptoms [49]. In this study, and others [50],
the use of systemic ivermectin did not completely eradicate
Demodex mites. However, the correlation between the observed
reduction of clinical symptoms and reduced Demodex infestation
in patients treated with ivermectin strengthens the argument that
Demodex mites play a significant role in the manifestations of OR
and related symptoms [49]. The authors of this study proposed the
use of ivermectin in conjunction with other therapies to challenge
Demodex infestation which may be associated with the symptoms
of blepharitis. Indeed, combination therapy involving ivermectin
and metronidazole has shown excellent clinical outcomes in
treating individuals with facial rosacea and blepharitis [50]. A
comparison of individuals treated with a combination of metroni-
dazole and ivermectin rather than with ivermectin in isolation,
showed a greater reduction in the Demodex population in
individuals treated with the combined therapy than with
ivermectin alone. The anti-inflammatory properties of metronida-
zole are thought to reduce the symptoms of inflammation that may
be caused by Demodex-associated antigens and it has been
suggested that metronidazole also has acricidal effects, which
may complement the anti-Demodex activity of ivermectin [50].
2. Conclusion
Many factors may influence the appearance and progression of
rosacea. The altered immune response in the skin may make it
more sensitive to stimuli that under normal conditions do not
provoke a response. The altered sebum content on rosacea skin
may favour the increased density of Demodex mites which may be
stimulatory. Alternatively the mites may carry bacteria which are
released upon their death within the pilosebaceous unit and which
then stimulate the immune response. A better understanding of
the complex relationship between the various factors that
influence the onset, persistence and progression of rosacea, may
facilitate the development of novel therapies that target the
cellular and molecular mechanisms responsible for the pathogen-
esis of this disfiguring disorder.
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